Standout Papers

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhib... 2006 2026 2012 2019 3.0k
  1. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes (2006)
    Daniel J. Drucker, Michael A. Nauck The Lancet
  2. Biology of Incretins: GLP-1 and GIP (2007)
    Laurie L. Baggio, Daniel J. Drucker Gastroenterology
  3. The biology of incretin hormones (2006)
    Daniel J. Drucker Cell Metabolism
  4. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1 (2018)
    Daniel J. Drucker Cell Metabolism
  5. Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action (2013)
    Jonathan E. Campbell, Daniel J. Drucker Cell Metabolism
  6. Normalization of obesity-associated insulin resistance through immunotherapy (2009)
    Shawn Winer, Yin Chan et al. Nature Medicine
  7. Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways (2008)
    Kiwon Ban, M. Hossein Noyan-Ashraf et al. Circulation
  8. FTO Obesity Variant Circuitry and Adipocyte Browning in Humans (2015)
    Melina Claussnitzer, Simon N. Dankel et al. New England Journal of Medicine
  9. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study (2008)
    Daniel J. Drucker, John B. Buse et al. The Lancet
  10. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection (2003)
    Matthew J. During, Lei Cao et al. Nature Medicine
  11. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. (1996)
    Daniel J. Drucker, Porat M. Erlich et al. Proceedings of the National Academy of Sciences
  12. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. (1987)
    Daniel J. Drucker, Jan Philippé et al. Proceedings of the National Academy of Sciences
  13. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon–like peptide 1 receptor gene (1996)
    Louise A. Scrocchi, Theodore J. Brown et al. Nature Medicine
  14. Incretin-based therapies for type 2 diabetes mellitus (2009)
    Julie A. Lovshin, Daniel J. Drucker Nature Reviews Endocrinology
  15. Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation (2010)
    Lotte Bjerre Knudsen, Søren Andersen et al. Endocrinology
  16. The Cardiovascular Biology of Glucagon-like Peptide-1 (2016)
    Daniel J. Drucker Cell Metabolism
  17. Advances in oral peptide therapeutics (2019)
    Daniel J. Drucker Nature Reviews Drug Discovery
  18. Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors (2014)
    Erin E. Mulvihill, Daniel J. Drucker Endocrine Reviews
  19. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors (2017)
    Michael A. Nauck, Juris J. Meier et al. Circulation
  20. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure (2013)
    Minsuk Kim, Mathew J. Platt et al. Nature Medicine
  21. Discovery, characterization, and clinical development of the glucagon-like peptides (2017)
    Daniel J. Drucker, Joel F. Habener et al. Journal of Clinical Investigation
  22. Insulin Secretion Depends on Intra-islet Glucagon Signaling (2018)
    Berit Svendsen, Olav Larsen et al. Cell Reports
  23. GLP-1 physiology informs the pharmacotherapy of obesity (2021)
    Daniel J. Drucker Molecular Metabolism
  24. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action (2023)
    John R. Ussher, Daniel J. Drucker Nature Reviews Cardiology
  25. Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation (2020)
    Brent A. McLean, Chi Kin Wong et al. Endocrine Reviews
  26. Diabetes, obesity, metabolism, and SARS-CoV-2 infection: the end of the beginning (2021)
    Daniel J. Drucker Cell Metabolism
  27. Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1 (2022)
    Rola Hammoud, Daniel J. Drucker Nature Reviews Endocrinology
  28. Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity (2024)
    Daniel J. Drucker Diabetes Care
  29. Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation (2023)
    Chi Kin Wong, Brent A. McLean et al. Cell Metabolism
  30. The expanding incretin universe: from basic biology to clinical translation (2023)
    Daniel J. Drucker, Jens J. Holst Diabetologia
  31. Diabetes mellitus—Progress and opportunities in the evolving epidemic (2024)
    E. Dale Abel, Anna L. Gloyn et al. Cell
  32. The benefits of GLP-1 drugs beyond obesity (2024)
    Daniel J. Drucker Science
  33. The GLP-1 journey: from discovery science to therapeutic impact (2024)
    Daniel J. Drucker Journal of Clinical Investigation
  34. GLP-1-based therapies for diabetes, obesity and beyond (2025)
    Daniel J. Drucker Nature Reviews Drug Discovery

Immediate Impact

1 by Nobel laureates 32 from Science/Nature 108 standout
Sub-graph 1 of 19

Citing Papers

A comprehensive spatio-cellular map of the human hypothalamus
2025 StandoutNature
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
2024 Standout
11 intermediate papers

Works of Daniel J. Drucker being referenced

GIP regulates inflammation and body weight by restraining myeloid-cell-derived S100A8/A9
2018
Normalization of obesity-associated insulin resistance through immunotherapy
2009 Standout
and 30 more

Author Peers

Author Last Decade Papers Cites
Daniel J. Drucker 35375 23641 19884 421 57.7k
Bo Åhrén 15941 12468 9921 717 32.4k
Bart Staels 12793 16704 40867 781 77.2k
C. Ronald Kahn 13599 14266 36433 511 73.3k
Jerrold M. Olefsky 15228 12227 34169 588 70.4k
Morris F. White 10421 12289 32584 343 50.8k
Steven E. Kahn 20367 12627 12423 467 45.2k
Joel F. Habener 12520 13758 13680 331 30.9k
Jeffrey S. Flier 12229 8997 22394 307 79.2k
David J. Mangelsdorf 7524 21964 39650 221 69.2k
Roger H. Unger 13138 14617 11070 407 35.4k

All Works

Loading papers...

Rankless by CCL
2026